Phosphorus Containing Other Than Solely As Part Of An Inorganic Ion In An Addition Salt Doai Patents (Class 514/75)
  • Patent number: 10131686
    Abstract: The invention relates to compositions, methods, kits, and assays related to the use and/or exploitation of isomers of cGAMP as well as the structure of the enzyme cGAS.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: November 20, 2018
    Assignees: Memorial Sloan Kettering Cancer Center, The Rockefeller University, Rutgers, The State University of New Jersey, University of Bonn
    Inventors: Dinshaw J. Patel, Thomas Tuschl, Manuel Ascano, Jr., Yang Wu, Yizhou Liu, Winfried Barchet, Gunther Hartmann, Thomas Zillinger, Roger Jones, Barbara L. Gaffney, Pu Gao
  • Patent number: 9782387
    Abstract: A compound represented by Formula I is provided for use in the treatment of a hematological malignancy in a subject in need thereof. Also provided are compositions and kits which comprise the compound.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: October 10, 2017
    Assignee: Tel HaShomer Medical Research Infrastructure and Services Ltd.
    Inventors: Merav Leiba, Gabriela Rozic
  • Patent number: 9775828
    Abstract: The present invention provides a pharmaceutical composition including an ionic liquid composed of a triptan compound and saccharin. Since a triptan compound and saccharin form an ionic liquid to increase the solubility of the triptan compound in the present invention, it is possible to expect a rapid and high dissolution of the triptan compound when a pharmaceutical composition is prepared. In addition, large amounts of organic solvents and acidic solvents need not be used in order to dissolve the triptan compound.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: October 3, 2017
    Assignee: University-Industry Foundation, Yonsei University
    Inventors: Sung-Joo Hwang, Han Kang, In-ho Song, Sang Min Hyun, Min Jun Kwon, Taek Sun Kim, Sitaram Prasad Velaga
  • Patent number: 9750766
    Abstract: Compositions comprising therapeutically effective amounts of lamellar bodies to restore lubricity and non-stick properties to mucous surfaces for conditions characterized by dry adherent surfaces, particularly those surfaces close to the body openings and conditions of the eye.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: September 5, 2017
    Assignee: Lamellar Biomedical Limited
    Inventor: James Dobbie
  • Patent number: 9683256
    Abstract: Disclosed are compositions for isolating populations of nucleic acids from biological, forensic, and environmental samples. Also disclosed are methods for using these compositions as one-step formulations for killing pathogens, inactivating nucleases, and releasing polynucleotides from other cellular components within the sample, and stabilizing the nucleic acids prior to further processing or assay. The disclosed compositions safely facilitate rapid sample collection, and provide extended storage and transport of the samples at ambient or elevated temperature without contamination of the sample or degradation of the nucleic acids contained therein. This process particularly facilitates the collection of specimens from remote locations, and under conditions previously considered hostile for preserving the integrity of nucleic acids released from lysed biological samples without the need of refrigeration or freezing prior to molecular analysis.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: June 20, 2017
    Assignee: Longhorn Vaccines and Diagnostics, LLC
    Inventors: Gerald W. Fischer, Luke T. Daum
  • Patent number: 9370492
    Abstract: The present invention provides novel solid pharmaceutical dosage forms for oral administration comprising a bisphosphonate, or a pharmaceutically acceptable salt thereof, which bisphosphonate is present in an amount not therapeutically effective when the bisphosphonate is orally administered alone, and a modified amino acid carrier, or a pharmaceutically acceptable salt thereof, which modified amino acid carrier is present in an amount effective to facilitate absorption of the bisphosphonate in the gastrointestinal tract such that the bisphosphonate is therapeutically effective. The ratio of bisphosphonate to modified amino acid carrier is from about 1:30 to about 1:1, respectively. These novel solid pharmaceutical dosage forms are useful in the treatment or control of bone diseases and particular disorders in calcium metabolism, including, for example, osteoporosis, hypercalcaemia of cancer, and the treatment of metastatic bone pain.
    Type: Grant
    Filed: July 16, 2009
    Date of Patent: June 21, 2016
    Assignee: EMISPHERE TECHNOLOGIES, INC.
    Inventors: Hashim Ahmed, Lewis Bender, Martin Howard Infeld, Shingai Majuru, Wantanee Phuapradit, Navnit Hargovindas Shah, Zhongshui Yu
  • Patent number: 9288983
    Abstract: A biocidal composition comprising 2,2-dibromomalonamide and an electrophile containing biocide, and its use for the control of microorganisms in aqueous and water-containing systems.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: March 22, 2016
    Assignee: Dow Global Technologies LLC
    Inventors: Bei Yin, Freddie L. Singleton
  • Patent number: 9212399
    Abstract: Disclosed are compositions for isolating populations of nucleic acids from biological, forensic, and environmental samples. Also disclosed are methods for using these compositions as one-step formations for killing pathogens, inactivating nucleases, and releasing polynucleotides from other cellular components within the sample, and stabilizing the nucleic acids prior to further processing or assay. The disclosed compositions safely facilitate rapid sample collection, and provide extended storage and transport of the samples at ambient or elevated temperature without contamination of the sample or degradation of the nucleic acids contained therein. This process particularly facilitates the collection of specimens from remote locations, and under conditions previously considered hostile for presenting the integrity of nucleic acids released from lysed biological samples without the need of refrigeration or freezing prior to molecular analysis.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: December 15, 2015
    Assignee: Longhorn Vaccines and Diagnostics, LLC
    Inventors: Gerald W Fischer, Luke T. Daum
  • Patent number: 9198845
    Abstract: Compounds of the formula (I) or salts thereof, wherein R1 represents alkyl, aryl, alkyl-aryl or aryl-alkyl, compositions containing same, and their use in counteracting human axillary malodour.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: December 1, 2015
    Assignee: Givaudan S.A.
    Inventors: Andreas Natsch, Thierry Granier
  • Patent number: 9173901
    Abstract: Compositions comprising therapeutically effective amounts of lamellar bodies for the modification of linear macromolecules are disclosed. These lamellar compositions are useful in the treatment of conditions or diseases characterized by a preponderance of heavy mucous secretions, such as otitis media, cystic fibrosis, bronchitis, sinusitis and nasal congestion. Methods of treating these diseases and conditions by administering a therapeutically effective amount of a composition to a patient requiring such treatment are also disclosed.
    Type: Grant
    Filed: November 24, 2008
    Date of Patent: November 3, 2015
    Assignee: LAMELLAR THERAPEUTICS LIMITED
    Inventor: James Dobbie
  • Patent number: 9102649
    Abstract: The present invention relates to compounds of Formula I and Formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of Formula I and Formula II; and formulated to treat an underlying etiology by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: August 11, 2015
    Inventor: Mahesh Kandula
  • Patent number: 9023763
    Abstract: Compounds which are trehalose-6-phosphate or trehalose-6-phosphonate precursors of formula (I) or agriculturally acceptable salts thereof are provided: (I) The compounds are useful in increasing starch production in plants.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: May 5, 2015
    Assignee: Isis Innovation Limited
    Inventors: Ram Sagar, Lucia F. Primavesi, Matthew J. Paul, Benjamin G. Davis
  • Publication number: 20150111852
    Abstract: The concept is put forward here that heat abstraction sensations, captured by topical application of a molecule, can be used to alleviate discomfort of non-keratinizng tissues. By synthesizing compounds and devising tests, a molecule name DAPA-2-5 was identified as having the selective desirable properties for achieving this purpose. DAPA-2-5 is a di-alkyl-phosphinoyl-alkane, and “DAPA-2-5” is 1-Di(sec-butyl)-phosphinoyl-pentane. DAPA-2-5 evokes a dynamic cooling sensation on non-keratinizing body surfaces (including, e.g., oropharyngeal, esophageal, and anogenital surfaces) which is not accompanied by stinging, irritation, or unpleasant tastes. Thus, it can be used to treat (e.g., suppress) sensory discomfort from non-keratinizing stratified epithelium (NKSE) selectively. This unusual selectivity, potency, and efficacy was also surprisingly exhibited in laboratory animal tests of inhibition of heat-induced edema, of eliciting skin irritation, and of inhibition of acid-induced swallowing.
    Type: Application
    Filed: November 18, 2014
    Publication date: April 23, 2015
    Inventor: Edward T. Wei
  • Publication number: 20150105349
    Abstract: Short-chain 2- to 3-carbon alcohols are used as solvents for cooling agents in the preparation of topical therapeutic and cosmetic formulations. Some of these alcohols, especially ethanol, inhibit the ability of the cooling agent to activate its target receptor. In one embodiment of this invention, (R)-1,2-propanediol is used as an alcoholic solvent for the topical delivery of cooling agents to biological surfaces. This (R)-1,2-propanediol enantiomer has a minimum inhibitory effect on cooling with respect to standard 2- to 3-carbon alcoholic solvents, and functions to substantially protect the agents cooling activity from inhibition when in the presence of a short-chain alcohol such as ethanol.
    Type: Application
    Filed: August 19, 2013
    Publication date: April 16, 2015
    Inventor: Edward T. Wei
  • Patent number: 9006216
    Abstract: A combination biocide (Glutaraldehyde or OPA), quaternary phosphonium biocide (preferably TTPC), alcohol (preferably isopropyl alcohol), and functional excipients for the oil and gas recovery industry. The functional excipients for the oil and gas recovery industry are a cellulose type proppant, a poloxamer wetting agent, a friction-reducing pluronic block copolymer, a drag reducing agent such as polyethylene oxide, and a flocculating agent. The OPA may be of the dialdehyde C6H4(CHO)2 form, and the Glutaraldehyde of formula C5H8O2. Both will produce an inherent bacteriostatic effect and lower surface tension and thus aids in the spread of the TTPC on the biofilm covered surface where it is readily absorbed by the negative surfaces of proteins and bacteria. It thus serves as a binding agent between the TTPC and the application surface. The foregoing constituents are combined in preferred concentrations within acceptable ranges to provide a synergistic biological chemical complementarity system.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: April 14, 2015
    Inventor: Howard Martin
  • Patent number: 8980226
    Abstract: A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass median aerodynamic diameter predominantly between 1 to 5?, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: March 17, 2015
    Assignee: Gilead Sciences, Inc.
    Inventors: William Baker, David MacLeod
  • Patent number: 8940927
    Abstract: The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinase activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: May 25, 2011
    Date of Patent: January 27, 2015
    Assignee: Metabasis Therapeutics, Inc.
    Inventors: Feng Tian, Qun Dang, G. Sridhar Prasad, Wenyu Li, Brett C. Bookser, Nicholas Brian Raffaele, Mark D. Erion
  • Patent number: 8912124
    Abstract: The invention relates to derivatives of (1-cyanocyclopropyl)phenylphosphinic acid of the formula (I) and to salts thereof, of the formula (II), for enhancing stress tolerance in plants to abiotic stress, preferably to drought stress, especially for enhancing plant growth and/or for increasing plant yield.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: December 16, 2014
    Assignee: Bayer Cropscience AG
    Inventors: Lothar Willms, Hans-Joachim Zeiβ, Marco Busch, Christopher Hugh Rosinger, Ines Heinemann, Isolde Häuser-Hahn, Martin Jeffrey Hills, Pascal Von Koskull-Döring
  • Patent number: 8901170
    Abstract: Compounds of formula (I) wherein the symbols have the meaning given in the specification, as well as processes for preparing the compounds (I), pesticidal compositions and synergistic mixtures comprising compounds (I), methods for the control of insects, acarids or nematodes by contacting the pests or their food supply, habitat or breeding grounds with a pesticidally effective amount of compounds formula (I), and a method for treating, controlling, preventing or protecting animals against infestation or infection by parasites which comprises orally, topically or parenterally administering or applying to the animals a parasiticidally effective amount of compounds of formula (I).
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: December 2, 2014
    Assignee: BASF SE
    Inventors: Matthias Pohlman, Michael Hofmann, Henricus Maria Martinus Bastiaans, Michael Rack, Deborah L. Culbertson, Hassan Oloumi-Sadeghi, Takeo Hokama, Christopher Palmer
  • Patent number: 8889592
    Abstract: The present invention relates to boosting the action of crop protection compositions comprising in particular spiroheterocyclically substituted tetramic acid derivatives of the formula (I) by addition of ammonium or phosphonium salts and optionally penetrants, to the corresponding compositions, to processes for their preparation and to their use in crop protection as insecticides and/or acaricides and/or for preventing unwanted vegetation.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: November 18, 2014
    Assignee: Bayer CropScience AG
    Inventors: Reiner Fischer, Stefan Lehr, Olga Malsam, Rolf Pontzen, Elmar Gatzweiler, Rainer Sussmann
  • Publication number: 20140296185
    Abstract: The present invention relates to a solid formulation of soap stick type comprising a primary surfactant, at least one binding agent and at least one dispersant that may especially be an amphoteric surfactant, optionally with additives. The present invention also relates to uses of said formulation, especially for oilfield applications, e.g. for gas well deliquification applications.
    Type: Application
    Filed: November 2, 2012
    Publication date: October 2, 2014
    Inventors: Christopher Raymond Jones, Kevan Hatchman, Alan Christopher Fellows
  • Patent number: 8835409
    Abstract: 3-Alkenyl-6-halo-4-aminopicolinic acids and their derivatives are potent herbicides demonstrating a broad spectrum of weed control.
    Type: Grant
    Filed: January 24, 2012
    Date of Patent: September 16, 2014
    Assignee: Dow AgroSciences, LLC.
    Inventors: Joseph D. Eckelbarger, Jeffrey B. Epp, Paul R. Schmitzer, Thomas L. Siddall
  • Publication number: 20140248270
    Abstract: A method of treating a tar-responsive dermatological disorder includes topically applying an anhydrous tar composition to skin of a mammal, preferably a human, that is involved with the disorder, the composition including a wax and a therapeutically effective amount of tar for topical treatment of the tar-responsive dermatological disorder, the composition being in liquid form when at a temperature selected from room temperature and a temperature of skin of a mammal upon application of the composition to the skin of the mammal.
    Type: Application
    Filed: May 13, 2014
    Publication date: September 4, 2014
    Inventors: Ruey J. YU, Eugene J. VAN SCOTT
  • Patent number: 8815227
    Abstract: The present invention provides, among other things, polymeric reagents suitable for reaction with biologically active agents to form conjugates, the polymeric reagents comprising one or more polymer chains and a plurality of hydroxyapatite-targeting moieties, and optionally the reagents include one or more degradable linkages that serve to divide the polymer chains into polymer segments having a molecular weight suitable for renal clearance.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: August 26, 2014
    Assignee: Nektar Therapeutics
    Inventors: Samuel P. McManus, Antoni Kozlowski
  • Publication number: 20140228290
    Abstract: The invention provides compositions and methods to treat cancer with an agent that increases reactive oxygen species (ROS) levels in cancer cell mitochondria (“an XTPP agent”) or a pharmaceutically acceptable salt thereof, an inhibitor of hydroperoxide metabolism and a pharmaceutically acceptable diluent or carrier.
    Type: Application
    Filed: August 2, 2012
    Publication date: August 14, 2014
    Applicants: REGENTS OF THE UNIVERSITY OF MICHIGAN, UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Douglas R. Spitz, Michael K. Schultz, Kyle Kloepping, Yueming Zhu, Nukhet Aykin-Burns, Max S. Wicha
  • Patent number: 8778838
    Abstract: The present invention relates to aqueous concentrate formulations for plant protection comprising: 2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1-(2H)pyrimidinyl]-4-fluoro-N-[[methyl(1-methylethyl)amino]sulfonyl]benzamide in the form of its anhydrate; N-(phosphonomethyl)glycine in the form of its free acid, in the form of the ammonium salt or a substituted ammonium salt or a mixture thereof; at least two different non-ionic surfactants with at least one of them comprising an ethylene oxide polymer moiety or an ethylene oxide/C3-C4-alkylene oxide block copolymer moiety, and water; wherein the pH-value of the formulation is below 6.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: July 15, 2014
    Assignee: BASF SE
    Inventors: Michael Krapp, Wolfgang Gregori, Sven Adam, Klaus Kolb, Juergen Jakob, Bernd Sievernich, Joerg Steuerwald, Steven Bowe, Joseph Zawierucha, Rex Liebl
  • Patent number: 8778914
    Abstract: The present invention relates to a prodrug, comprising a pharmaceutically and/or diagnostically active compound, and one or more bisphosphonate groups, to a process for producing such a prodrug, and to a pharmaceutical composition comprising said prodrug, to be used for the treatment of bone-related disorders such as bone cancer.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: July 15, 2014
    Assignee: KTB Tumorforschungsgesellschaft mbH
    Inventors: Felix Kratz, Katrin Hochdoerffer
  • Publication number: 20140193553
    Abstract: The present application relates to a new method for treating fruits or vegetables comprising the use of hot phosphorous acid (PA) as well as PA-based combinations and corresponding kits.
    Type: Application
    Filed: December 30, 2013
    Publication date: July 10, 2014
    Applicant: XEDA INTERNATIONAL
    Inventor: Alberto SARDO
  • Patent number: 8722648
    Abstract: The inventions relates to a liquid pharmaceutical form containing an active ingredient alkylphosphocholines and a co-solvent system. The co-solvent system is mixture from hexylene glycol, propylene glycol, diethylene glycol monoethyl ether and water. The pharmaceutical form having a pH value in the range of 4 to 6, which if it is necessary can be achieved by adding a pH adjuster. The composition has a good storage stability and it is suitable for local application on the different organs of the body. The inventions relates also to a method for producing the same pharmaceutical form.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: May 13, 2014
    Inventor: Paul Meng
  • Patent number: 8716363
    Abstract: Disclosed are phospholipid based compositions and implant devices, as well as methods and kits that include such compositions or components thereof. In particular, the present compositions include a polymer component such as a poloxamer or PEG component and a phospholipid component, such as a Phosal. The present compositions may include at least one additional component, such as granules, powder and/or particulates. The present compositions may further include one or more bone graft materials and/or active ingredients. The compositions may be used on their own or incorporated on or in a surgical implant.
    Type: Grant
    Filed: September 28, 2011
    Date of Patent: May 6, 2014
    Assignee: Globus Medical, Inc.
    Inventor: Vipin Kunjachan
  • Patent number: 8709454
    Abstract: At least one phytosphingosine salicylate derivative and at least one lysate of at least one microorganism of the genus Bifidobacterium. Composition, combination. Use, including cosmetic use for reinforcing the repair and regeneration capacity of an epithelium, especially an epidermis, in particular an aged epidermis.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: April 29, 2014
    Assignee: L'Oreal
    Inventors: David Amar, Bruno Bernard, Dominique Bernard, Isabelle Castiel
  • Patent number: 8691580
    Abstract: In an embodiment the instant invention discloses a modular composition comprising 1) an oligonucleotide; 2) one or more linkers, which may be the same or different, selected from Table 1, wherein the linkers are attached to the oligonucleotide at any 3? and/or 5? end; 3) one or more peptides, which may be the same or different, selected from SEQ ID NOs: 1-59, wherein the peptides are attached to the linkers; and optionally one or more lipids, solubilizing groups and/or targeting ligands attached to the oligonucleotide.
    Type: Grant
    Filed: April 4, 2011
    Date of Patent: April 8, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jeffrey G. Aaronson, Stanley F. Barnett, René Bartz, Steven L. Colletti, Vasant R. Jadhav, Aaron A. Momose, Anthony W. Shaw, David M. Tellers, Thomas J. Tucker, Weimin Wang, Yu Yuan
  • Publication number: 20140080769
    Abstract: The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype.
    Type: Application
    Filed: September 13, 2013
    Publication date: March 20, 2014
    Applicants: The Chancellor, Masters and Scholars of the University of Oxford, The Government of the United States of America, as represented by the Secretary, Department of Healt
    Inventors: Frances Mary Platt, Emyr Lloyd-Evans, Forbes Dennison Porter
  • Publication number: 20140080793
    Abstract: The present invention is related to pharmaceutical compositions that include a phosphonium antimicrobial agent. In a preferred embodiment, the present invention relates to an otic, nasal or ophthalmic composition (e.g., an aqueous ophthalmic solution) that includes a phosphonium salt compound as an antimicrobial agent. The compositions typically possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements and/or similar preservative standards (e.g., EP and JP).
    Type: Application
    Filed: November 20, 2013
    Publication date: March 20, 2014
    Applicant: Alcon Research, Ltd.
    Inventors: Masood A. Chowhan, Wesley Wehsin Han, L. Wayne Schneider
  • Patent number: 8673882
    Abstract: Stabilized benzyl phosphonic acid and naphthyl phosphonic acid analog compounds are effective in inhibiting the activity of autotaxin.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: March 18, 2014
    Assignee: University of Tennessee Research Foundation
    Inventors: Renuka Gupte, Renukadevi Patil, Gabor Tigyi, Duane D. Miller
  • Patent number: 8669240
    Abstract: Disclosed are compositions for isolating populations of nucleic acids from biological, forensic, and environmental samples. Also disclosed are methods for using these compositions as one-step formulations for killing pathogens, inactivating nucleases, and releasing polynucleotides from other cellular components within the sample, and stabilizing the nucleic acids prior to further processing or assay. The disclosed compositions safely facilitate rapid sample collection, and provide extended storage and transport of the samples at ambient or elevated temperature without contamination of the sample or degradation of the nucleic acids contained therein. This process particularly facilitates the collection of specimens from remote locations, and under conditions previously considered hostile for presenting the integrity of nucleic acids released from lysed biological samples without the need of refrigeration or freezing prior to molecular analysis.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: March 11, 2014
    Assignee: Longhorn Vaccines & Diagnostics, LLC
    Inventors: Gerald W. Fischer, Luke T. Daum
  • Patent number: 8658600
    Abstract: Disclosed is a general methodology to create nano fibers of therapeutic molecules that have a dual role, as both the delivery vehicle and the drug itself. It is shown that with proper molecular design, the integration of enzymatic reaction and self-assembly provides a powerful method to create molecular hydrogels of clinically-used therapeutics without compromising their bioactivities. In addition, the results disclosed herein demonstrate enzyme-instructed self-assembly as a facile strategy for generating the supramolecular hydrogels of molecules that inherently have poor solubility in water. For example, by covalently connecting paclitaxel with a motif that is prone to self-assemble, a hydrogel of paclitaxel can be formed without compromising the activity of the paclitaxel.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: February 25, 2014
    Assignee: Brandeis University
    Inventors: Yuan Gao, Yi Kuang, Bing Xu
  • Patent number: 8657943
    Abstract: 1-OH-2-acyl-sn-glycero-3-phosphocholine compounds and its analogs, pure or mixed, having formula WCH2CHXCH2PO3YCH2CH2Z, where W is preferably a hydroxyl group or an O-acyl group containing from 2 to 22 carbon atoms, and where X is preferably an O-acyl group containing from 2 to 22 carbon atoms or a hydroxyl (OH) and where Y may be an (O?) or OH and where Z is preferably a trimethyl-ammonium group [N+(CH3)3] can be protonated dimethyl ammonium [N+H(CH3)2] group. In the O-acyl groups containing 18 carbon atoms can be observed from 0 to 3 instaurations, useful as biocidal agents; processes for their preparation; and antifouling compositions, preferably paints useful in susceptible fouling surfaces, such as hulls of vessels. Methods to turn a surface into an antifouling surface, to a method to prevent fouling and to the antifouling surfaces comprising a coating of the said antifouling composition.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: February 25, 2014
    Assignee: UFRJ, IEAPM, UFF
    Inventors: William Romao Batista, Ricardo Coutinho, Maria Campos Beta Neves, Claudio Cerqueira Lopes, Rosangela Sabbatini Lopes, Vanessa de Almeida Martins, Renato Crespo Pereira
  • Publication number: 20130345171
    Abstract: Provided herein are compositions for the treatment and/or prevention of cardiovascular disease (CVD), and methods of application and use thereof. In particular, the present invention provides treatment and/or prevention of cardiovascular disease with compounds that inhibit the production of TMA in the gut, such as 3,3-dimethyl-1-butanol (DMB) or other compounds represented by Formula I or as shown in FIGS. 20-23.
    Type: Application
    Filed: June 11, 2013
    Publication date: December 26, 2013
    Inventors: Stanley L. Hazen, Bruce Levison, Zeneng Wang
  • Patent number: 8609142
    Abstract: The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: December 17, 2013
    Assignee: BIND Therapeutics, Inc.
    Inventors: Greg Troiano, Michael Figa, Abhimanyu Sabnis
  • Patent number: 8609636
    Abstract: The present invention relates to novel oxime derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: December 17, 2013
    Assignee: Allergan, Inc.
    Inventors: Wenkui K. Fang, Liming Wang, Evelyn G. Corpuz, Ken Chow, Wha-Bin Im
  • Patent number: 8604078
    Abstract: The present invention relates to a solid fosfomycin pharmaceutical composition stable in front the coloration, suitable for diabetics and not entailing gastrointestinal problems. The pharmaceutical composition of this invention comprises fosfomycin trometamol, glycine, and optionally other excipients as sucralose, silice dioxide, polyvinylpyrrolidone and flavor; and is substantially free from sugars and sugar alcohols as sucrose, fructose, glucose, xylitol, mannitol, sorbitol or mixtures thereof.
    Type: Grant
    Filed: March 19, 2012
    Date of Patent: December 10, 2013
    Inventor: Carlos Picornell Darder
  • Patent number: 8603437
    Abstract: The present invention discloses a method for the enzyme-mediated, site-specific, in-vivo precipitation of a water soluble molecule in an animal. The enzyme is either unique to tumor cells, or is produced within a specific site (e.g., tumor) at concentrations that are higher than that in normal tissues. Alternatively, the enzyme is conjugated to a targeting moiety such as an antibody or a receptor-binding molecule.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: December 10, 2013
    Assignee: President and Fellows of Harvard College
    Inventors: Amin I. Kassis, Ravi S. Harapanhalli
  • Patent number: 8598084
    Abstract: An herbicide/insecticide composition containing (a) a pyridine carboxylic acid component and (b) an insecticide component provides synergistic control of selected weeds.
    Type: Grant
    Filed: February 17, 2011
    Date of Patent: December 3, 2013
    Assignee: Dow AgroSciences, LLC.
    Inventors: Norbert M. Satchivi, Paul R. Schmitzer
  • Publication number: 20130280165
    Abstract: The invention is directed to a method for preparing a microsphere comprising a lanthanide metal phosphate complex, a microsphere, a powder comprising a number of the microspheres, a suspension comprising the microsphere or the powder, the use of the microsphere, a method for detecting a tumour, and a therapeutic composition comprising the microsphere, the powder, or the suspension.
    Type: Application
    Filed: November 4, 2011
    Publication date: October 24, 2013
    Applicant: UMC Utrecht Holding B.V.
    Inventors: Wouter Bult, Johannas Franciscus Wilhelmus Nijsen, Alfred Drik Van het Schip
  • Publication number: 20130259953
    Abstract: A combination biocide (Glutaraldehyde or OPA), quaternary phosphonium biocide (preferably TTPC), alcohol (preferably isopropyl alcohol), and functional excipients for the oil and gas recovery industry. The functional excipients for the oil and gas recovery industry are a cellulose type proppant, a poloxamer wetting agent, a friction-reducing pluronic block copolymer, a drag reducing agent such as polyethylene oxide, and a flocculating agent. The OPA may be of the dialdehyde C6H4(CHO)2 form, and the Glutaraldehyde of formula C5H8O2. Both will produce an inherent bacteriostatic effect and lower surface tension and thus aids in the spread of the TTPC on the biofilm covered surface where it is readily absorbed by the negative surfaces of proteins and bacteria. It thus serves as a binding agent between the TTPC and the application surface. The foregoing constituents are combined in preferred concentrations within acceptable ranges to provide a synergistic biological chemical complementarity system.
    Type: Application
    Filed: May 21, 2013
    Publication date: October 3, 2013
    Inventor: Howard Martin
  • Publication number: 20130251822
    Abstract: A combination biocide (Glutaraldehyde or OPA), quaternary phosphonium biocide, alcohol, and functional excipients for surface-sterilization of medical instruments and other objects. The quaternary phosphonium biocide is preferably TTPC, and the alcohol isopropyl alcohol. The OPA is the dialdehyde C6H4(CHO)2, which produces an inherent bacteriostatic effect, lowering surface tension, and aiding in the spread of the TTPC on the instrument surface where it is readily absorbed by the negative surfaces of proteins and bacteria. It thus serves as a binding agent between the TTPC and the application surface.
    Type: Application
    Filed: May 21, 2013
    Publication date: September 26, 2013
    Inventor: Howard Martin
  • Patent number: 8541395
    Abstract: The present invention is directed to the use of telocinobufagin, or its pharmaceutically acceptable derivatives, in the manufacture of a medicament for the treatment or prevention of acute and chronic pains. The present invention also refers to a pharmaceutical composition comprising an effective amount of telocinobufagin; also provides a method to induce analgesia in response to acute and chronic pains that comprehends administering an effective amount of telocinobufagin to human beings or animals. According to the outcomes of in vivo assays, telocinobufagin is more potent than morphine, though without presenting the known side effects of opioids. In addition, in vivo and in vitro essays showed that TBC does not present cardiotoxicity.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: September 24, 2013
    Assignees: Cristalia Produtos Quimicos Farmaceuticos Ltda., Genpharma Consultoria Farmaceutica E Genetica Ltda.
    Inventors: Krishnamurti De Morais Carvalho, Dòris Maria Fernandes Carvalho, Maria Denise Fernandes Carvalho, Ogari de Castro Pacheco, Roberto Carlos Debom Moreira
  • Publication number: 20130236404
    Abstract: The invention provides methods of preventing or treating a condition associated with DNA damage in an animal comprising the administration of a substance that interferes with the activity of the CUL4A ubiquitin ligase. The invention also provides a substance that interferes with the activity of CUL4A, as well as compositions comprising the interfering substance and a carrier. The substance of the invention preferably enhances nucleotide excision repair activity in an animal. The invention further provides methods of identifying substances that negatively or positively modulate the expression and/or activity of CUL4A.
    Type: Application
    Filed: April 29, 2009
    Publication date: September 12, 2013
    Applicant: Cornell University
    Inventor: Pengbo ZHOU
  • Patent number: 8529915
    Abstract: Short-chain 2- to 3-carbon alcohols are used as solvents for cooling agents in the preparation of topical therapeutic and cosmetic formulations. Some of these alcohols, especially ethanol, inhibit the ability of the cooling agent to activate its target receptor. In one embodiment of this invention, (R)-1,2-propanediol is used as an alcoholic solvent for the topical delivery of cooling agents to biological surfaces. This propanediol enantiomer has a minimum inhibitory effect on cooling with respect to standard 2- to 3-carbon alcoholic solvents, and functions to substantially protect the agent's cooling activity from inhibition when in the presence of a short-chain alcohol.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: September 10, 2013
    Inventor: Edward T. Wei